Načítá se...
MRD evaluation of AML in clinical practice: are we there yet?
MRD technologies increase our ability to measure response in acute myeloid leukemia (AML) beyond the limitations of morphology. When applied in clinical trials, molecular and immunophenotypic MRD assays have improved prognostic precision, providing a strong rationale for their use to guide treatment...
Uloženo v:
| Vydáno v: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Hematology
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913462/ https://ncbi.nlm.nih.gov/pubmed/31808906 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000060 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|